Assessment of Fetal Pancreatic Size and Maternal Serum Biomarkers in GDM

Haseki Training and Research Hospital109 enrolled

Overview

The investigators aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabetes mellitus (GDM).In this prospective observational study including 109 pregnant women, the fetal pancreas size and maternal serum biomarkers GA and IRAP were measured at the gestational age of 20-22 weeks and later at the gestational age of 24-28 weeks, in 19 participants of them, GDM was confirmed with the 75-g oral glucose tolerance test (OGTT) and the fetal pancreas size was measured in all the participants again.

Study Type

OBSERVATIONAL

Enrollment

109

Conditions

Gestational Diabetes

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 42 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Maternal age between 18 and 42 years * Gestational age between 20 and 28 weeks Exclusion Criteria: * Multiple pregnancies * Pregestational diabetes * Fetal congenital malformations * Placental and amniotic fluid abnormalities * Preeclampsia * Severe systemic disease * Long-term systemic drug usage

Locations (1)

Haseki Training and Research Hospital

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

Early prediction of gestational diabetes

Early prediction of gestational diabetes by the fetal pancreas measurement with ultrasound and maternal serum biomarkers glycated albumin and insulin-regulated aminopeptidase measured with ELISA

Time frame: Two months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.